Viral pneumonia Full details for md exam answer 15 marks introduction etiology pathogenesis clinical features and diagnostic and treatment complications drug dosage
Reading File
Finding Sources
Finding Sources
Now I'll read the key sections in parallel — Murray & Nadel (primary respiratory textbook), Rosen's Emergency Medicine, Robbins Pathology, and Goldman-Cecil Medicine:
Reading File
Reading File
Reading File
Reading File
Excellent. Now let me get the Fishman's Pulmonary detailed section and search for more specific content on pathology, treatment, and complications:
Reading File
Finding Sources
Finding Sources
The Fishman's section is very comprehensive. Let me continue reading it and also get the treatment section:
Reading File
Finding Sources
Let me read the Goldman-Cecil antivirals section and continue Fishman's treatment section:
Reading File
Reading File
Searching PubMed
"viral pneumonia" treatment antiviral
Now let me get the key treatment sections from Fishman's and also get the diagnostic criteria and complications section:
Reading File
I now have extensive material. Let me update the todos and compile the comprehensive answer:---
VIRAL PNEUMONIA — Comprehensive MD Exam Answer (15 Marks)
1. INTRODUCTION / DEFINITION
Viral pneumonia is an acute inflammatory infection of the lung parenchyma caused by viruses, characterized by involvement of the alveoli, bronchioles, and interstitium. It represents a clinically significant entity that affects both immunologically intact and immunocompromised hosts. It is distinct from bacterial pneumonia in its pathology, clinical presentation, and management approach.
Viral pneumonia is more common in infants and young children; in healthy adults, pure viral pneumonia is relatively rare and predominantly caused by influenza. In the elderly and immunocompromised, a broader spectrum of viruses causes significant morbidity and mortality. — Fishman's Pulmonary Diseases and Disorders
2. ETIOLOGY
Viruses causing pneumonia are classified by host age and immune status:
Common Viral Agents
| Virus | Key Features |
|---|---|
| Influenza A & B | Most common cause in adults; pandemic potential |
| Respiratory Syncytial Virus (RSV) | #1 cause in infants < 2 years |
| Parainfluenza virus (types 1–4) | Croup + pneumonia in children |
| Human Metapneumovirus (hMPV) | Children and elderly; similar to RSV |
| Adenovirus | Military recruits, children (~10% of childhood pneumonias) |
| Rhinovirus | Mainly URTI; occasional LRT involvement |
| Coronavirus (including SARS-CoV-2) | COVID-19, SARS, MERS |
| Measles (rubeola) | Giant cell pneumonia; complication in immunosuppressed |
| Varicella-Zoster (VZV) | Varicella pneumonia; severe in pregnancy and immunosuppressed |
| Cytomegalovirus (CMV) | Immunocompromised (transplant, AIDS); secondary systemic infection |
| Hantavirus | Hantavirus pulmonary syndrome |
| Herpes Simplex Virus (HSV) | Severe immunosuppression |
| Epstein-Barr Virus (EBV) | Lymphocytic interstitial pneumonitis |
Risk factors for progression to pneumonia: extremes of age, malnutrition, alcoholism, underlying cardiopulmonary disease (COPD, valvular heart disease), pregnancy, immunosuppression, obesity.
— Robbins, Cotran & Kumar Pathologic Basis of Disease; Fishman's Pulmonary Diseases
3. PATHOGENESIS
General Mechanism
Viruses causing pneumonia share a common pathogenic sequence:
- Entry: Viral attachment to respiratory epithelial cells via specific surface receptors (e.g., influenza hemagglutinin binds sialic acid residues on ciliated epithelium)
- Replication: Intracellular viral replication → cytopathic changes → cell death
- Inflammation: Secondary inflammatory response with neutrophilic and mononuclear infiltration
- Defense impairment: Mucociliary clearance is disrupted → predisposes to bacterial superinfection
Three pathophysiologic patterns are recognized:
- Primary viral pneumonia: Infection confined to respiratory tract (influenza, RSV)
- Respiratory onset with systemic spread: Measles, varicella
- Secondary respiratory involvement from systemic infection: CMV
— Fishman's Pulmonary Diseases and Disorders
Influenza (Model Pathogen)
Influenza A encodes hemagglutinin (H) and neuraminidase (N) surface proteins:
- Hemagglutinin (H) — attaches to sialic acid receptors on ciliated airway epithelium → endosomal fusion → release of viral RNA into cytoplasm
- Neuraminidase (N) — cleaves sialic acid residues to release newly formed virions from infected cells
- Viral genome: 8 single-stranded RNA segments; type determined by nucleoproteins (A, B, C)
- Antigenic drift: Spontaneous point mutations in H or N → new variants eluding prior immunity (annual epidemics)
- Antigenic shift: Reassortment of gene segments between human and animal influenza strains → novel subtypes → pandemics
Microscopic pathology of primary influenza pneumonia:
- Widespread destruction of ciliated epithelial cells of trachea, bronchi, bronchioles
- Hyperemic mucosa, focal hemorrhage, edema, cellular infiltrate in submucosa
- Alveolar spaces: neutrophils + mononuclear cells + fibrin + edema fluid
- Intra-alveolar hemorrhage; hyaline membranes lining alveolar ducts (diffuse alveolar damage pattern)
- RSV/parainfluenza in children: bronchiolar mucus plugging, epithelial necrosis, peribronchial mononuclear infiltration, cytoplasmic inclusion bodies
Bacterial superinfection mechanism:
Viral injury disrupts epithelial barrier, impairs mucociliary clearance, and type I interferon responses downregulate antibacterial defenses → enhanced bacterial pathogenesis — Fishman's Pulmonary Diseases
4. CLINICAL FEATURES
Prodromal / Systemic Phase (1–4 days)
- Abrupt onset of high-grade fever (38.5–40°C), chills, rigors
- Severe myalgia (legs, back), arthralgias, headache
- Profound malaise, prostration
- Upper respiratory: nasal congestion, sore throat, hoarseness, rhinorrhea
Pulmonary Phase (days 3–7)
- Nonproductive cough (dominant symptom)
- Progressive dyspnea, tachypnea
- Frothy, pink-tinged sputum in severely ill patients
- Cyanosis in severe disease
- Tachycardia disproportionate to fever
- Physical examination:
- Acutely ill appearance
- Conjunctivitis, rhinitis
- Tracheal tenderness (viral tracheitis)
- Diffuse bilateral crackles (rales) and wheezes
- Reduced air entry in areas of consolidation
Age-specific variations
- Infants: Apneic episodes, grunting, retractions, cyanosis, lethargy, dehydration; may present with minimal fever
- Children: Wheezing, associated croup or bronchiolitis; tachypnea may be the only finding
- Elderly: More severe lower respiratory signs from agents that cause only URTI in young adults
Special Virus-specific Features
| Virus | Distinctive Features |
|---|---|
| Measles | Koplik spots, maculopapular rash, leukopenia; giant cell pneumonia in immunosuppressed |
| Varicella | Vesicular rash; pneumonia 3–5 days after rash onset; more severe in adults and pregnancy |
| RSV | Bronchiolitis, wheezing, hyperinflation; infants < 6 months |
| Adenovirus | Hilar adenopathy; DIC as late feature; severe in military recruits |
| CMV | Interstitial pneumonitis in transplant/AIDS patients |
— Fishman's Pulmonary Diseases; Rosen's Emergency Medicine
5. DIAGNOSIS
A. Clinical Diagnosis
- Seasonal presentation (predominantly winter)
- Acute onset fever + myalgia + nonproductive cough
- More gradual onset than typical bacterial pneumonia
B. Chest X-Ray (CXR)
- Typical: Diffuse bilateral interstitial infiltrates (interstitial pattern)
- Peribronchial thickening and hyperinflation (especially in children with RSV)
- Patchy areas of consolidation (lobular atelectasis)
- Lobar consolidation and pleural effusion are atypical (suggest bacterial cause)
- Adenovirus: hilar lymphadenopathy more common
- No CXR pattern reliably distinguishes viral from bacterial pneumonia
C. Laboratory Tests
| Test | Findings |
|---|---|
| CBC | Leukopenia or normal WBC; lymphopenia in influenza; leukocytosis suggests bacterial superinfection |
| Sputum Gram stain | Scant, few PMNs, minimal bacteria |
| CRP / Procalcitonin | Low procalcitonin favors viral etiology |
| Blood cultures | Usually negative |
| LFTs | May be mildly elevated |
| Arterial Blood Gas | Hypoxemia; in severe disease, Type I respiratory failure (↓PaO₂, normal/↓PaCO₂) |
D. Virological Tests
| Test | Details |
|---|---|
| Rapid antigen tests | Influenza: 50–70% sensitivity; rapid results (< 30 min); low sensitivity limits utility |
| Molecular tests (RT-PCR) | Gold standard; highly sensitive and specific; nasopharyngeal swab; detects influenza, RSV, parainfluenza, adenovirus, coronavirus, rhinovirus, hMPV |
| Multiplex PCR panels | Simultaneously detect 15–20 respiratory viruses |
| Viral culture | Gold standard for characterization; slow (days to weeks); epidemiological importance |
| Direct fluorescent antibody (DFA) | Moderate sensitivity; rapid; useful for RSV |
| Serology (paired titers) | 4-fold rise in antibody titer = retrospective diagnosis; 2–4 weeks apart |
| BAL / bronchoscopy | Immunocompromised patients for CMV, RSV, adenovirus |
E. CT Chest
- Ground-glass opacities (bilateral, peripheral) — especially COVID-19
- Mosaic attenuation, tree-in-bud pattern
- Useful when CXR is equivocal
— Fishman's Pulmonary Diseases; Murray & Nadel; Goldman-Cecil Medicine
6. TREATMENT
General Supportive Measures
- Rest, adequate hydration, nutrition
- Antipyretics (paracetamol/acetaminophen) for fever and myalgia
- Supplemental oxygen — target SpO₂ > 94%
- Mechanical ventilation if respiratory failure (lung-protective ventilation in ARDS)
- Prone positioning in severe ARDS
Specific Antiviral Drug Treatment
A. INFLUENZA (A & B)
Neuraminidase Inhibitors (first-line):
| Drug | Route | Adult Dose | Notes |
|---|---|---|---|
| Oseltamivir (Tamiflu) | Oral | 75 mg twice daily × 5 days | Most widely used; bioavailability >75% |
| Zanamivir (Relenza) | Inhaled | 10 mg twice daily × 5 days (two 5 mg inhalations) | Poor oral bioavailability; avoid in asthma/COPD |
| Peramivir | IV | 600 mg single IV dose | For hospitalized/unable to take oral |
Endonuclease Inhibitor (newer):
| Drug | Route | Adult Dose | Notes |
|---|---|---|---|
| Baloxavir marboxil (Xofluza) | Oral | ≤80 kg: 40 mg single dose; >80 kg: 80 mg single dose | Cap-dependent endonuclease inhibitor; single dose convenience |
Adamantanes (older, limited use due to resistance):
| Drug | Route | Adult Dose | Notes |
|---|---|---|---|
| Amantadine | Oral | 100 mg twice daily or 200 mg once daily × 5 days | Influenza A only; widespread resistance |
| Rimantadine | Oral | 100 mg twice daily × 5 days | Influenza A only; less CNS side effects than amantadine |
Timing is critical: Treatment is most effective when started within 48 hours of symptom onset. For hospitalized, severe, or high-risk patients, treatment should be initiated regardless of time since onset.
Mechanism of neuraminidase inhibitors: Sialic acid analogues that competitively inhibit viral neuraminidase → block release of newly formed virions from infected cells → prevent viral spread within respiratory tract.
— Goldman-Cecil Medicine; Fishman's Pulmonary Diseases
B. RSV
| Drug | Route | Dose | Indication |
|---|---|---|---|
| Ribavirin | Inhaled aerosol | SPAG unit, 12–18 hrs/day × 3–7 days | Severe RSV in immunocompromised |
| Palivizumab | IM | 15 mg/kg monthly × 5 doses (Oct–Feb) | Prophylaxis only; high-risk infants (prematurity, CHD) |
| Nirsevimab | IM | 50 mg (< 5 kg) or 100 mg (≥ 5 kg) single dose | Newer monoclonal antibody; approved for RSV prevention in infants/toddlers |
C. VARICELLA PNEUMONIA
| Drug | Route | Adult Dose | Notes |
|---|---|---|---|
| Acyclovir | IV | 10–15 mg/kg every 8 hours × 7–10 days | Drug of choice; reduces mortality especially in pregnancy |
- VZIG (varicella-zoster immune globulin) within 96 hours of exposure for susceptible immunocompromised/pregnant patients
D. CMV PNEUMONIA (in immunocompromised)
| Drug | Route | Dose | Notes |
|---|---|---|---|
| Ganciclovir | IV | 5 mg/kg every 12 hours × 14–21 days | First-line; often combined with IV immunoglobulin in CMV pneumonitis post-transplant |
| Valganciclovir | Oral | 900 mg twice daily × 21 days | Oral prodrug of ganciclovir; maintenance therapy |
| Foscarnet | IV | 60 mg/kg every 8h or 90 mg/kg every 12h | For ganciclovir-resistant CMV |
E. ADENOVIRUS
No antiviral with proven clinical efficacy. Cidofovir (IV) used in severe/immunocompromised cases; brincidofovir (oral) under evaluation.
F. COVID-19 PNEUMONIA
| Drug | Indication | Dose |
|---|---|---|
| Remdesivir | Hospitalized patients requiring O₂ | 200 mg IV Day 1, then 100 mg IV daily × 4 days (5-day course) |
| Dexamethasone | Requiring O₂/ventilation | 6 mg once daily × 10 days (oral or IV) |
| Nirmatrelvir-ritonavir (Paxlovid) | High-risk outpatient | 300 mg/100 mg twice daily × 5 days |
| Baricitinib | Hospitalized with severe disease | 4 mg once daily × 14 days |
Antibiotic Co-treatment
For viral pneumonia complicated by or suspected of bacterial coinfection:
- Outpatient: Amoxicillin or azithromycin
- Inpatient (non-severe): β-lactam (ceftriaxone 1–2 g/day) + macrolide (azithromycin 500 mg/day) OR respiratory fluoroquinolone (levofloxacin 750 mg/day)
- Inpatient (severe): β-lactam + macrolide OR β-lactam + fluoroquinolone
- Add vancomycin/linezolid if MRSA suspected
— Goldman-Cecil Medicine
7. COMPLICATIONS
Pulmonary Complications
- Primary progressive viral pneumonia — severe bilateral pneumonia with diffuse alveolar damage, hypoxemic respiratory failure, ARDS; carries high mortality
- Bacterial superinfection (most important) — secondary bacterial pneumonia 2–14 days after initial viral illness (classic "biphasic" illness): recurrence of fever + new lobar consolidation
- Common pathogens: S. aureus (including MRSA), S. pneumoniae, H. influenzae
- Bronchiolitis obliterans (especially adenovirus in children) — obliterative bronchiolitis with persistent airflow obstruction
- Pleural effusion (uncommon in viral pneumonia per se)
- Empyema (complicates bacterial superinfection)
Systemic Complications
- Respiratory failure / ARDS — diffuse alveolar damage pattern; requires mechanical ventilation
- Myocarditis and pericarditis — particularly influenza, adenovirus, enterovirus
- Encephalitis / Neurological — febrile seizures (children), Reye's syndrome (aspirin + influenza in children), encephalopathy
- Septic shock — secondary to bacterial superinfection or direct viral sepsis
- Disseminated intravascular coagulation (DIC) — adenovirus, severe influenza, hantavirus
- Dehydration — particularly in children and elderly
- Apnea — infants < 3 months with RSV
Complications in Special Populations
- Pregnancy: Increased ICU admission, mechanical ventilation, preterm birth, thromboembolic disease (COVID-19 especially)
- Immunocompromised: Disseminated viral infection (CMV, adenovirus), prolonged shedding, higher mortality
- Children: Apnea, febrile seizures, croup, bronchiolitis
8. PREVENTION
- Annual influenza vaccination (inactivated injectable or live attenuated intranasal) — all individuals > 6 months; mandatory in pregnant women, elderly, healthcare workers
- COVID-19 vaccination (mRNA vaccines: BNT162b2, mRNA-1273)
- RSV prophylaxis: Palivizumab (high-risk infants), nirsevimab
- Varicella vaccine (live attenuated) — contraindicated in pregnancy and immunosuppressed
- Infection control: Hand hygiene, respiratory etiquette, droplet/airborne precautions
SUMMARY TABLE — Antiviral Drug Dosages at a Glance
| Virus | Drug | Route | Dose | Duration |
|---|---|---|---|---|
| Influenza A/B | Oseltamivir | PO | 75 mg BD | 5 days |
| Influenza A/B | Zanamivir | Inhaled | 10 mg BD | 5 days |
| Influenza A/B | Peramivir | IV | 600 mg | Single dose |
| Influenza A/B | Baloxavir | PO | 40–80 mg | Single dose |
| Influenza A | Amantadine | PO | 100 mg BD / 200 mg OD | 5 days |
| Varicella | Acyclovir | IV | 10–15 mg/kg TDS | 7–10 days |
| CMV | Ganciclovir | IV | 5 mg/kg BD | 14–21 days |
| RSV | Ribavirin aerosol | Inhaled | SPAG unit 12–18 h/day | 3–7 days |
| COVID-19 | Remdesivir | IV | 200 mg → 100 mg OD | 5 days |
| COVID-19 | Dexamethasone | PO/IV | 6 mg OD | 10 days |
| COVID-19 | Nirmatrelvir/r | PO | 300/100 mg BD | 5 days |
Sources: Fishman's Pulmonary Diseases and Disorders | Murray & Nadel's Textbook of Respiratory Medicine | Robbins, Cotran & Kumar Pathologic Basis of Disease | Goldman-Cecil Medicine | Rosen's Emergency MedicineThis is a comprehensive, examination-ready answer covering all sections you requested. Here is a quick orientation guide:
How to Use This Answer for 15 Marks
| Section | Marks Allocation (approx.) |
|---|---|
| Introduction + Definition | 1 mark |
| Etiology (viral agents + risk factors) | 2 marks |
| Pathogenesis (molecular + histopathology) | 3 marks |
| Clinical Features (adult, pediatric, virus-specific) | 2 marks |
| Diagnosis (clinical, CXR, lab, virological tests) | 2 marks |
| Treatment + Drug Dosages (all antivirals) | 3 marks |
| Complications | 2 marks |
| Total | 15 marks |
Key Exam Points to Remember
- Influenza hemagglutinin (H) = attachment to sialic acid; Neuraminidase (N) = release of virions — targeted by oseltamivir/zanamivir
- Antigenic drift (gradual mutation) = annual epidemics; Antigenic shift (gene reassortment) = pandemic
- CXR shows bilateral interstitial infiltrates (not lobar consolidation) in primary viral pneumonia
- Oseltamivir 75 mg BD × 5 days is the first-line for influenza; must start within 48 hours
- Bacterial superinfection (S. aureus, S. pneumoniae) is the most important complication — classic biphasic illness pattern
- Acyclovir IV = treatment for varicella pneumonia (especially in pregnancy)
- Dexamethasone 6 mg/day × 10 days reduces mortality in COVID-19 requiring oxygen
- Procalcitonin is low in viral pneumonia, high in bacterial — useful differentiating biomarker
- Hyaline membrane formation on histology = diffuse alveolar damage (worst-case influenza/COVID-19)
- Reye's syndrome = never give aspirin to children with viral (especially influenza/varicella) illness
This is a shared conversation. Sign in to Orris to start your own chat.